Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948819 | 0.88 | HTR6 (0.55) | HTR6CCNE1CDK2PTGDR2 | |
| SCHEMBL3886933 | 0.84 | HTR6 (0.66) | HTR6CCNE1CDK2CYP2C19HTR1A | |
| SCHEMBL1772540 | 0.83 | HTR6 (0.64) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL1049380 | 0.82 | HTR6 (0.55) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL3888242 | 0.81 | HTR6 (0.68) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL28140601 | 0.80 | HTR6 (0.57) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL1267767 | 0.80 | CYP2C19 (0.56) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL12675767 | 0.79 | HTR6 (0.56) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL1773129 | 0.79 | HTR6 (0.58) | HTR6CCNE1CDK2CYP2C19MET | |
| SCHEMBL28312453 | 0.79 | HTR6 (0.55) | HTR6CCNE1CDK2CYP2C19MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HTR6 1928/4885CCNE1 86/4885CDK2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.